Improving outcomes and combating AMR by giving the best drug every time

iFAST is addressing the $4bn (& growing) Antimicrobial Susceptibility Testing (AST) market.
We have a test that is up to 10x faster and cheaper than the gold standard, delivering results in 4 hours for urine samples and 8 hours for sepsis, saving lives and reducing the spread of antimicrobial resistance.

Article in the Sunday telegraph

Super-fast test to select right antibiotic is likely lifesaver

British researchers have pioneered a test that can cut the time it takes to identify the right antibiotic treatment from three days to four hours, potentially saving thousands of lives.

Improving outcomes and combating AMR by giving the best drug every time

iFAST is addressing the $4bn (& growing) Antimicrobial Susceptibility Testing (AST) market.
We have a test that is up to 10x faster and cheaper than the gold standard, delivering results in 4 hours for urine samples and 8 hours for sepsis, saving lives and reducing the spread of antimicrobial resistance.

The Problem

Bacteria are increasingly resistant to antibiotics – resistance levels are 20% - 98% and unpredictable. Current Antimicrobial Susceptibility Testing (AST) takes 48 -72 hours – patients deteriorate whilst waiting for the correct drug.

Prescribing inappropriate antibiotics leads to the spread of resistant infections, sepsis and death
Antimicrobial resistance (AMR) caused over 1 million deaths in 2019 – more than malaria or AIDS

iFAST reduces AST test time from 48+ to 4 hours

Blood/urine sample Incubated

Sample incubated for
a few hours then exposed to
range of antibiotics

Test itself takes
30 seconds

After a further 1 hour incubation, reader scans 5,000 individual bacteria

RESISTANT/
SUSCEPTIBLE Output

iFAST reader determines
optimum antibiotic for clinician to prescribe

The Benefits of iFAST

Speed

Results in only 4 hours (urine)
– 8 hours (blood) from raw sample

High throughput

Each reader performs
> 100 tests/day

Cost

Cheaper than current
gold standard methods

Small lab footprint

Reader is only 600x600mm
and fits neatly on a lab bench

Each sample analysed in less than a minute

The electrical properties of single bacteria are measured at high speed in a microfluidic chip.

Experienced and committed team

Dr Toby King

CEO

Lorem ipsum dolor sit amet, consec tetur adipiscing elit.
Prof Hywel Morgan

CTO

Lorem ipsum dolor sit amet, consec tetur adipiscing elit.
Dr Dan Spencer

VP Engineering

Lorem ipsum dolor sit amet, consec tetur adipiscing elit.
Prof Mark Sutton

Advisory Board Chair

Lorem ipsum dolor sit amet, consec tetur adipiscing elit.

Research system will be available in 2023, with clinical system expected to launch in 2024.

To find out more

If you would like find out more please send us
an email and we will get in touch.

Find our presentation, nature paper below & synopsis for hospitals below.

Get in Touch

+44 (0)7788 595176

toby@ifastdiagnostics.com

 

Based in the United Kingdom